The biotech and infectious disease world — much of the world, really — sat eagerly anticipating the early Covid-19 vaccine data AstraZeneca and the Lancet had promised would emerge on Monday. Then, at 9:30 EST, the Lancet posted not only the AstraZeneca data but a second batch of important results: the Phase II data from Chinese biotech CanSino Biologics.
AstraZeneca, Moderna and Pfizer, among others, have captured much of the attention in Europe and North America, where countries have helped usher the vaccines through trials and signed deals for hundreds of millions of doses. But CanSino was the first of any effort to report Phase I data and they’ve rolled along at the front of the pack since.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 85,500+ biopharma pros reading Endpoints daily — and it’s free.